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Summary
Background Human genetic factors are important determinants of malaria risk. We investigated associations between 
multiple candidate polymorphisms—many related to the structure or function of red blood cells—and risk for severe 
Plasmodium falciparum malaria and its specific phenotypes, including cerebral malaria, severe malaria anaemia, and 
respiratory distress.
Methods We did a case-control study in Kilifi County, Kenya. We recruited as cases children presenting with severe 
malaria to the high-dependency ward of Kilifi County Hospital. We included as controls infants born in the local 
community between Aug 1, 2006, and Sept 30, 2010, who were part of a genetics study. We tested for associations 
between a range of candidate malaria-protective genes and risk for severe malaria and its specific phenotypes. We 
used a permutation approach to account for multiple comparisons between polymorphisms and severe malaria. 
We judged p values less than 0·005 significant for the primary analysis of the association between candidate genes 
and severe malaria.
Findings Between June 11, 1995, and June 12, 2008, 2244 children with severe malaria were recruited to the study, and 
3949 infants were included as controls. Overall, 263 (12%) of 2244 children with severe malaria died in hospital, 
including 196 (16%) of 1233 with cerebral malaria. We investigated 121 polymorphisms in 70 candidate severe malaria-
associated genes. We found significant associations between risk for severe malaria overall and polymorphisms in 
15 genes or locations, of which most were related to red blood cells: ABO, ATP2B4, ARL14, CD40LG, FREM3, INPP4B, 
G6PD, HBA (both HBA1 and HBA2), HBB, IL10, LPHN2 (also known as ADGRL2), LOC727982, RPS6KL1, CAND1, 
and GNAS.  Combined, these genetic associations accounted for 5·2% of the variance in risk for developing severe 
malaria among individuals in the general population. We confirmed established associations between severe malaria 
and sickle-cell trait (odds ratio [OR] 0·15, 95% CI 0·11–0·20; p=2·61 × 10–⁵⁸), blood group O (0·74, 0·66–0·82; 
p=6·26 × 10–⁸), and –α³·⁷-thalassaemia (0·83, 0·76–0·90; p=2·06 × 10–⁶). We also found strong associations between 
overall risk of severe malaria and polymorphisms in both ATP2B4 (OR 0·76, 95% CI 0·63–0·92; p=0·001) and 
FREM3 (0·64, 0·53–0·79; p=3·18 × 10–¹⁴). The association with FREM3 could be accounted for by linkage 
disequilibrium with a complex structural mutation within the glycophorin gene region (comprising GYPA, GYPB, 
and GYPE) that encodes for the rare Dantu blood group antigen. Heterozygosity for Dantu was associated with risk 
for severe malaria (OR 0·57, 95% CI 0·49–0·68; p=3·22 × 10–¹¹), as was homozygosity (0·26, 0·11–0·62; p=0·002).
Interpretation Both ATP2B4 and the Dantu blood group antigen are associated with the structure and function of red 
blood cells. ATP2B4 codes for plasma membrane calcium-transporting ATPase 4 (the major calcium pump on red 
blood cells) and the glycophorins are ligands for parasites to invade red blood cells. Future work should aim at 
uncovering the mechanisms by which these polymorphisms can result in severe malaria protection and investigate 
the implications of these associations for wider health.
Funding Wellcome Trust, UK Medical Research Council, European Union, and Foundation for the National Institutes 
of Health as part of the Bill & Melinda Gates Grand Challenges in Global Health Initiative.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Plasmodium falciparum malaria has had a pre-eminent 
role in child mortality within tropical regions for the past 
5000 years. This mosquito-transmitted infection spends 
most of its lifecycle in human beings within red blood 
cells, in which it multiplies approximately ten times every 
2 days until controlled by either immunity or treatment. 
Chronic asymptomatic and repeated uncomplicated 
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malaria episodes cause high levels of childhood anaemia 
and undernutrition in malaria-endemic areas, whereas 
severe malaria—including severe malarial anaemia, 
cerebral malaria, and respiratory distress—is associated 
with high acute mortality.1
Malaria has had a major effect on the human genome 
through selection of polymorphisms associated with 
improved survival.2 Some of these polymorphisms 
include the classic red-blood-cell variants sickle-cell trait 
and α+-thalassaemia. However, protection against malaria 
might also be afforded by other polymorphisms.3
Here, we describe the effect of a wide range of key 
genetic candidates—most of which relate to the structure 
and function of red blood cells—on risk for severe 
childhood malaria in the population of Kilifi in Kenya. 
The aim of our study was to verify the importance of 
specific candidates that could provide insights into the 
pathophysiology of severe malaria and that might be 
plausibly used to underpin the development of new 
approaches to prevention and treatment of this 
debilitating disease.
Methods
Study design and participants
Our study was set in Kilifi County on the coast of Kenya.4 
We investigated the effect of a range of candidate genes 
on risk for severe falciparum malaria, using a case-
control approach.
We included as cases children (aged <14 years) who 
presented to hospital with clinical features of severe 
malaria5–7 and were subsequently admitted to the high-
dependency ward of Kilifi County Hospital. We excluded 
children who presented before or after the recruitment 
dates and those without specific features of severe 
malaria. We focused our study on children, because in 
the context of most countries within sub-Saharan Africa, 
severe malaria is almost exclusively restricted to child-
hood.1 We categorised cases into the major pheno types of 
cerebral malaria, respiratory distress, severe malarial 
anaemia, and other severe malaria (which included 
clinical evidence of prostration, hypoglycaemia and 
hyperparasitaemia), as described elsewhere.5–7 We also 
classified cases based on their inpatient survival status. 
We used these categories on the basis that they are either 
associated with the highest rates of mortality7 or that they 
would probably have been associated with high mortality 
in the pretreatment era and, as such, have been strong 
drivers of Darwinian selection.
We included as controls infants (aged 3–12 months) 
who were born within the same study area as cases 
and who were recruits to a cohort study investigating 
genetic susceptibility to a range of childhood diseases.8 
We recruited roughly two controls for every case—a ratio 
we arrived at for pragmatic reasons.
Individual written informed consent was provided by 
the parents of all study participants. Ethics approval for 
Research in context
Evidence before this study
We searched PubMed between Jan 1, 1960, and May 30, 2018, 
with the terms (“malaria” AND “case-control”), (“malaria” AND 
“ATP2B4”), (“malaria” AND “FREM3”), and “Dantu”. We did not 
restrict our search by language. We supplemented our search with 
a review of reference lists within papers identified by our search 
and those from our personal records. Our search retrieved 
six papers containing data for malaria and ATP2B4 
(four case-control studies, one population genetic study, and one 
review article), two relevant papers relating to malaria and FREM3 
(one case-control study and one molecular genetic study), and 
one laboratory-based functional study relating to malaria and the 
rare blood group antigen Dantu. Although previous studies have 
highlighted associations between polymorphisms in ATP2B4 and 
FREM3 and malaria risk, they have lacked detail about the precise 
clinical effects of these polymorphisms. Moreover, previous 
studies have not confirmed that the association between FREM3 
and severe malaria is accounted for by close chromosomal linkage 
to the rare blood group antigen Dantu.
Added value of this study
We report the results of a large case-control study (n=6193) of 
severe Plasmodium falciparum malaria, undertaken in a carefully 
phenotyped population. We have described the effects of both 
ATP2B4 and Dantu on specific phenotypes of severe malaria, on 
parasite densities during malaria episodes, on haematological 
indices, and on death during hospital admission. Moreover, 
in all participants we genotyped 121 polymorphisms in 
70 candidate genes and could put associations into context 
with other candidate genes and quantify their overall effect on 
disease susceptibility. Presence of the Dantu mutation was 
associated with reductions in risk for severe malaria 
overall—43% among heterozygotes and 74% among 
homozygotes. Protection was equal for all forms of severe 
malaria and Dantu also protected against malaria-related 
death. Similarly, ATP2B4 was strongly protective against all 
forms of severe malaria but, moreover, was associated with 
lower parasite densities.
Implications of all the available evidence
Both the Dantu and ATP2B4 polymorphisms affect the 
membrane of red blood cells, which is the main target of malaria 
infection in human beings, yet the haematological outcomes of 
these polymorphisms remain unknown. In the case of the 
Plasmodium vivax form of human malaria, discovery of a strong 
protective association between negativity for the red cell blood 
group Duffy antigen has led directly to design of a promising 
vaccine. Discovering the mechanisms by which ATP2B4 and 
Dantu protect against severe P falciparum malaria offers similar 
potential for drug and vaccine development in the future.
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the study was granted by the Kenya Medical Research 
Institute and the National Ethical Review Committee in 
Nairobi, Kenya (SCC1192) and the Oxford Tropical Ethical 
Review Committee in Oxford, UK (020-06).
Procedures
We investigated the association between severe malaria 
and 129 single nucleotide polymorphisms (SNPs) plus 
one 3·7 kb deletion in 70 gene regions that had been 
identified as candidates through previous studies9 
(appendix pp 2–4). We did genotyping with the Sequenom 
MassARRAY iPLEX platform (Agena Biosciences, 
Hamburg, Germany;9 appendix pp 5, 6), using DNA 
extracted by proprietary methods (ABI PRISM, Applied 
Biosystems, Foster City, CA, USA; Qiagen DNA Blood 
Mini Kit, Qiagen, Crawley, UK) from fresh or frozen 
samples of whole blood obtained from participants. 
We genotyped samples for the common African form 
of α+-thalassaemia (3·7 kb deletion in HBA1 and HBA2 
[–α³·⁷-thalassaemia]) by PCR, as described previously,10,11 
and we used a BlpI restriction fragment length 
polymorphism assay (Thermo Fisher Scientific, Waltham, 
MA, USA) to type for the rare Dantu blood group antigen 
polymorphism (known as DUP4, a duplication copy 
number variant), as described previously.12
Outcomes
The primary outcome was the association between 
specific genetic polymorphisms and risk of severe 
P falciparum malaria both overall and in terms of specific 
phenotypes, expressed as odds ratios (ORs) for their 
frequency in cases compared with healthy uninfected 
controls. Secondary outcomes included associations 
between polymorphisms and inpatient mortality, 
and between polymorphisms and P falciparum parasite 
densities among severe malaria cases, as judged from 
peripheral blood smears.
Statistical analysis
We ascertained the sample size for this study prag-
matically, as the number of children presenting to 
Kilifi County Hospital during the study period who were 
eligible for inclusion as cases. We included roughly 
two controls for every case to maximise power. We did all 
analyses using R.
Of the 130 polymorphisms assayed, we removed nine 
before analysis after standard quality-control procedures. 
We removed eight SNPs because they were mono-
morphic and therefore non-contributory to the analysis 
(BCAS3 [rs184142841], GRIP1 [rs192909543], GUSBP5 
[rs148111931], LTBP2 [rs74063230], OXNAD1 [rs200704287, 
rs75180423, and rs79691057], and RHOG [rs138826089]) 
and one SNP was removed because more than 10% of 
genotypes were missing (PLEKHG1 [rs144224092]), 
making genotype calls unreliable (appendix pp 2–4). 
All remaining polymor ph isms passed a test for Hardy-
Weinberg equilibrium in the control sample using 
a threshold of p<0·0001 (this threshold includes a 
Bonferroni correction for the number of polymorphisms 
included in this study). Thus, 121 polymorphisms were 
analysed.
We calculated odds ratios (ORs) for associations of 
polymorphisms with risk for severe malaria and its 
major phenotypes, and for disease outcomes in terms of 
mortality, by comparing allele and genotype frequencies 
among cases and controls, using a fixed-effects logistic-
regression model. We adjusted analyses for the 
confounding effects of genetic background (using self-
reported ethnic origin) and the rs334 polymorphism in 
HBB. rs334 causes both sickle-cell trait and sickle-cell 
disease, which are major potential confounders in the 
interpretation of such analyses. Gender is also a known 
(albeit small) risk factor for malaria, both at a genetic 
level and at a sociocultural level; therefore, we used 
gender as a covariate in the autosomal polymorphism 
analyses. We did not look specifically at the effect of 
individual ethnic groups in Kilifi because of space and 
power considerations. In our primary analysis of severe 
malaria phenotypes, we allowed individual cases to be 
included more than once if they manifested more than 
one phenotype of severe malaria. In secondary analyses, 
we classified individuals uniquely based on relative 
mortality, using the hierarchy of cerebral malaria, severe 
malarial anaemia, respiratory distress, and other forms 
of severe malaria. For X-chromosome polymorphisms, 
we did analyses both overall and for each gender 
separately, based on our previous observations with the 
X-chromosome gene G6PD, in which we noted opposing 
effects in males and females that were undetectable in 
combined analyses.13 In all our analyses, we used a 
standard meta-analytical approach that utilised fixed 
effects (inverse-variance weighting) to account for 
unequal variance.14
We tested for associations between polymorphisms 
and risk for severe malaria using a range of different 
genetic models of inheritance (including additive, 
dominant, heterozygous, hemizygous, and recessive) 
and selected those that were most significant for each 
polymorphism. However, we analysed the SNP rs8176719 
under a recessive model only, because this model was 
the only one that allowed us to test for an association 
between severe malaria and blood group O. Doing more 
than one statistical test can lead to an increased chance 
of false-positives. We, therefore, used an appropriate 
significance cutoff (p<0·005), which accounted for the 
simulated distribution of potential p values, by 
permuting (randomly reassigning) the case or control 
status 1000 times using the SNPassoc package in R. We 
then used the lower bound of the 95% CI of the resulting 
p-value distribution (p≤0·005) as our significance level 
for all further analyses.15 We adjusted p values for gender, 
ethnic group, and rs334 genotype. Moreover, because 
epistasis has been reported between several malaria 
resistance polymorphisms,16 we also used a likelihood 
For more on R see 
http://www.r-project.org
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ratio approach11 to test for pairwise interactions between 
polymorphisms in autosomal chromosomes for which 
we identified significant associations with severe malaria 
in our primary analyses.
We assessed the proportion of the total variance in the 
overall risk of developing severe malaria at least once 
before the age of 14 years within Kilifi County that could be 
accounted for both by individual polymorphisms and 
overall. We analysed data on the raw (binomial), 
logit-transformed and probit-transformed scales under 
generalised linear models using the glm function in the 
stats package in R, with fixed effects for gender, ethnic 
group, and the genetic marker or set of markers 
(appendix pp 26, 27). We calculated estimates of the 
proportion of the total explained variation (variance) using 
R² statistics for analyses on the raw scale and McFadden’s 
pseudo-R² statistic when analysed on the transformed 
scale. We post-adjusted McFadden’s pseudo-R² statistic to 
the underlying disease liability scale, which we assumed to 
be normally distributed, using the method described by 
Lee and colleagues.17 This approach adjusts for dependency 
between variances of binomial traits on disease prevalence, 
thereby enabling comparisons of estimates between 
populations and studies. Since case-control studies have 
higher proportions of cases than in the general population 
(in our study, roughly 20 times higher), we adjusted 
variance estimates to reflect those in the general 
population,17 based on a designated lifetime prevalence of 
severe malaria in children younger than 14 years in the 
general population of 2·15% and the ratio of cases to 
controls (9:16). We calculated linkage disequilibrium using 
the genetics package in R.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
CMN, MM, KAR, and TNW had access to raw data. The 
corresponding author had full access to all data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Between June 11, 1995, and June 12, 2008, 2244 children 
presented to the high-dependency ward of Kilifi County 
Cases Controls 
(n=3949)
Severe malaria 
(n=2244)
Cerebral malaria 
(n=1233)
Severe malarial 
anaemia (n=686)
Respiratory distress 
(n=686)
Other severe malaria 
(n=436)
Age (months) 28·0 (15·0–43·0) 28·0 (16·0–43·0) 19·0 (10·0–33·0) 25·0 (12·7–38·0) 32·0 (19·2–54·0) 6·0 (5·0–8·0)
Male cases 1157 (52%) 627 (51%) 357 (52%) 357 (52%) 226 (52%) 1992 (50%)
Female cases 1087 (48%) 606 (49%) 329 (48%) 329 (48%) 210 (48%) 1957 (50%)
Ethnic origin
Giriama 1320 (59%) 743 (60%) 385 (56%) 379 (55%) 268 (62%) 1335 (46%)
Chonyi 527 (23%) 264 (21%) 176 (26%) 181 (26%) 97 (22%) 1411 (36%)
Kauma 171 (8%) 98 (8%) 48 (7%) 64 (9%) 25 (6%) 440 (11%)
Other 226 (10%) 128 (10%) 77 (11%) 62 (9%) 46 (10%) 273 (7%)
Parasite density per µL 
(geometric mean [95% CI])
40 032 
(36 141–44 343)
38 650 
(33 608–44 447)
40 944 
(34 590–48 465)
56 849 
(47 547–67 969)
34 701 
(27 111–44 416)
N/A
MCV (fL) 74·1 (9·4) 74·3 (9·3) 75·4 (10·6) 74·8 (9·8) 73·3 (8·9) N/A
Platelets (× 10⁶ per L) 163 (146) 170 (145) 139 (118) 154 (147) 168 (164) N/A
Haemoglobin (g/L) 66 (25) 70 (24) 38 (12) 63 (25) 79 (20) N/A
Inpatient death 263 (12%) 196 (16%) 82 (12%) 119 (17%) 21 (5%) N/A
Data are median (IQR), number of participants (%), or mean (SD), unless indicated otherwise. Severe malaria cases were classified as cerebral malaria, severe malarial anaemia, 
and respiratory distress; patients displaying more than one severe malaria phenotype are represented in each of the subgroups. MCV=mean cell volume. N/A=not applicable. 
Table 1: Clinical, demographic, and laboratory characteristics of study participants
Figure 1: Venn diagram showing the distribution of the three major 
phenotypes of severe malaria
Numbers indicate the cases for each phenotype or co-expressed phenotypes, and 
percentages are the case-fatality. Other severe malaria cases are those without 
any of the three phenotypes shown in the main diagram.
678
(13%)
283
(20%)
161
(8%)
89
(14%)
325
(6%)
153
(23%)119
(11%)
436
(5%)
Cerebral malaria n=1233 Other severe malaria
Respiratory distress n=686
Severe malarial anaemia n=686
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Figure 2: Distribution of p values for association tests with severe malaria phenotypes
The minimum p value (–log10[p]) for every polymorphism across the models is shown. We adjusted p values for gender, ethnic group, and rs334 genotype. The dashed 
vertical line represents the significance threshold of p<0·005, which was determined by permutation testing. The polymorphisms tested are listed in chromosomal 
order (appendix pp 2–4). 
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ATP2B4 (rs4951074)
ATP2B4 (rs3753036)
IL10 (rs3024500)
IL10 (rs1800896)
IL 10 (rs1800890)
CR1 (rs17047660)
CR1 (rs17047661)
LOC727982 (rs11371478)
LOC727982 (rs1371474)
LOC727982 (rs10188961)
LAPTM4A (rs973128)
SDC1 (rs11899121)
IL1A (rs17561)
IL1B (rs1143634)
ZSWIM2 (rs4316902)
ZSWIM2 (rs14478284)
IL 17RE (rs708567)
TLR9 (rs187084)
IL17RD (rs6780995)
ARL14 (rs76033371)
ARL14 (rs75731597)
ARL14 (rs74954675)
B3GALNT1 (rs12107243)
TLR1 (rs4833095)
TLR6 (rs5743810)
TLR6 (rs5743809)
INPP4B (rs77389579)
INPP4B (rs13103597)
USP38 (rs4266246)
USP38 (rs28459062)
GAB1 (rs7663712)
FREM3 (rs184908374)
FREM3 (rs149914432)
FREM3 (rs186790584)
FREM3 (rs184895969)
FREM3 (rs186873296)
C6 (rs1801033)
IRF1 (rs2706384)
IL13 (rs20541)
GABBR1 (rs192151845)
HCG4 (rs114980857)
LTA (rs2239704)
LTA (rs909253)
TNF (rs1799964)
TNF (rs1800750)
TNF (rs1800629)
TNF (rs361525)
TNF (rs3093662)
HSPA1B (rs6457452)
SNORD48 (rs116288147)
CTL4 (rs2242665)
IL20RA (rs1555498)
PLEKHG1 (rs55958968)
PLEKHG1 (rs79100774)
PLEKHG1 (rs114726617)
PLEKHG1 (rs2131263)
PLEKHG1 (rs76924464)
PLEKHG1 (rs151293197)
PLEKHG1 (rs142712208)
PLEKHG1 (rs15116938)
PLEKHG1 (rs141555199)
N0D1 (rs2075820)
CD36 (rs3211938)
TLR4 (rs4986790)
TLR4 (rs4986791)
ABO (rs8176750)
ABO (rs56390333)
ABO (rs8176746)
ABO (rs8176719)
MKI67 (rs11016116)
MKI67 (rs148494166)
MKI67 (rs115947774)
RRM1 (rs116472045)
HBB (rs334)
TRIM5 (rs7935564)
RTN3 (rs542998)
GRIP1 (rs1394263)
CAND1 (rs1566830)
CAND1 (rs12307123)
CAND1 (rs10459266)
IL22 (rs2227507)
IL22 (rs1012356)
IL22 (rs2227491)
IL22 (rs2227485)
IL22 (rs2227478)
TPTE2 (rs182873742)
SPTB (rs229587)
YLPM1 (rs101390160)
RPS6KL 1 (rs3742785)
HBA (–α³·⁷-thalassaemia)
ADCY9 (rs2230739)
ADCY9 (rs10775349)
IL4R (rs1805015)
IL4 (rs2243250)
ADORA2B (rs2535611)
NOS2 (rs2297518)
NOS2 (rs1800482)
NOS2 (rs9282799)
NOS2 (rs8078340)
TBX2 (rs73991577)
EMR1 (rs373533)
EMR1 (rs461645)
ICAM (rs5498)
GNAS (rs8316)
DERL3 (rs1128127)
CD40LG (rs3092945_ALL)
CD40LG (rs3092945_F)
CD40LG (rs3092945_M)
CD40LG (rs1126535_ALL)
CD40LG (rs1126535_F)
CD40LG (rs1126535_M)
G6PD (rs1050829_ALL)
G6PD (rs1050829_F)
G6PD (rs1050829_M)
G6PD (rs1050828_ALL)
G6PD (rs1050828_F)
G6PD (rs1050828_M)
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Frequency (%) of derived 
allele in controls 
(normal/het/hom [n])
Frequency (%) of derived 
allele in cases 
(normal/het/hom [n])
Model* Unadjusted Adjusted†
OR (95% CI) p value OR (95% CI) p value
ATP2B4 (rs1541255, chromosome 1; A→G)
Severe malaria 33% (1741/1774/418) 31% (1010/1016/185) R 0·74 (0·62–0·89) 0·001 0·76 (0·63–0·92) 0·001
Cerebral malaria 33% (1741/1774/418) 30% (581/549/96) R 0·68 (0·54–0·86) 0·001 0·69 (0·54–0·89) 0·001
Severe malarial anaemia 33% (1741/1774/418) 29% (323/293/49) R 0·63 (0·46–0·87) 0·003 0·60 (0·43–0·84) 0·003
Respiratory distress 33% (1741/1774/418) 30% (322/313/49) R 0·62 (0·46–0·85) 0·001 0·64 (0·46–0·88) 0·002
Death 33% (1741/1774/418) 31% (119/117/23) R 0·80 (0·51–1·25) 0·31 0·74 (0·46–1·29) 0·25
IL10 (rs1800890, chromosome 1; A→T)
Severe malaria 24% (2270/1418/257) 23% (1313/821/199) R 0·69 (0·55–0·88) 0·002 0·72 (0·56–0·93) 0·002
Cerebral malaria 24% (2270/1418/257) 23% (725/443/57) R 0·74 (0·55–0·99) 0·03 0·76 (0·55–0·99) 0·04
Severe malarial anaemia 24% (2270/1418/257) 24% (394/256/37) R 0·83 (0·58–1·19) 0·3 0·89 (0·62–1·30) 0·33
Respiratory distress 24% (2270/1418/257) 23% (400/252/33) R 0·75 (0·51–1·09) 0·12 0·75 (0·51–1·11) 0·12
Death 24% (2270/1418/257) 23% (156/86/16) R 0·96 (0·57–1·63) 0·9 0·98 (0·72–1·72) 0·97
LPHN2 (also known as ADGRL2; rs72933304, chromosome 1, C→A)
Severe malaria 8% (3297/619/26) 7% (1912/296/8) A 0·80 (0·69–0·92) 0·001 0·83 (0·72–0·96) 0·002
Cerebral malaria 8% (3297/619/26) 7% (1057/168/5) A 0·82 (0·69–0·98) 0·02 0·86 (0·71–0·99) 0·03
Severe malarial anaemia 8% (3297/619/26) 7% (570/93/3) A 0·85 (0·68–1·06) 0·15 0·88 (0·70–1·11) 0·17
Respiratory distress 8% (3297/619/26) 7% (587/93/3) A 0·83 (0·66–1·03) 0·09 0·85 (0·68–1·07) 0·11
Death 8% (3297/619/26) 6% (228/34/0) A 0·74 (0·51–1·05) 0·08 0·77 (0·53–1·11) 0·12
LOC727982 (rs1371478, chromosome 2; C→T)
Severe malaria 26% (2123/1466/320) 29% (1088/958/163) H 1·30 (1·17–1·45) 1·90 × 10⁻⁶ 1·35 (1·20–1·51) 2·31 × 10⁻⁶
Cerebral malaria 26% (2123/1466/320) 29% (606/536/84) H 1·31 (1·15–1·50) 4·61 × 10⁻⁵ 1·37 (1·19–1·57) 7·19 × 10⁻⁵
Severe malarial anaemia 26% (2123/1466/320) 30% (318/291/154) H 1·31 (1·11–1·55) 0·001 1·45 (1·22–1·74) 0·001
Respiratory distress 26% (2123/1466/320) 29% (331/308/43) H 1·38 (1·17–1·63) 0·0001 1·47 (1·23–1·74) 0·0001
Death 26% (2123/1466/320) 29% (126/116/21) H 1·34 (1·04–1·73) 0·02 1·42 (1·09–1·86) 0·02
ARL14 (rs75731597, chromosome 3, A→C)
Severe malaria 8% (2957/500/34) 10% (1754/401/18) H 1·27 (1·10–1·47) 0·001 1·25 (1·07–1·46) 0·001
Cerebral malaria 8% (2957/500/34) 10% (975/222/9) H 1·25 (1·05–1·49) 0·01 1·25 (1·04–1·51) 0·01
Severe malarial anaemia 8% (2957/500/34) 10% (520/119/7) H 1·27 (1·02–1·59) 0·03 1·30 (1·07–1·59) 0·04
Respiratory distress 8% (2957/500/34) 12% (546/119/5) H 1·23 (0·98–1·53) 0·06 1·28 (0·99–1·59) 0·08
Death 8% (2957/500/34) 10% (1754/401/18) H 1·45 (1·03–2·04) 0·01 1·55 (1·13–2·13) 0·01
FREM3 (rs186873296, chromosome 4, A→G)
Severe malaria 10% (3216/670/40) 6% (1967/233/6) A 0·57 (0·49–0·66) 4·23 × 10⁻¹⁴ 0·64 (0·53–0·79) 3·18 × 10⁻¹⁴
Cerebral malaria 10% (3216/670/40) 6% (1087/136/2) A 0·59 (0·49–0·71) 7·16 × 10⁻⁹ 0·63 (0·49–0·79) 1·12 × 10⁻⁸
Severe malarial anaemia 10% (3216/670/40) 5% (593/69/1) A 0·55 (0·43–0·70) 4·56 × 10⁻⁷ 0·67 (0·45–0·81) 8·20 × 10⁻⁷
Respiratory distress 10% (3216/670/40) 5% (611/68/3) A 0·53 (0·41–0·69) 4·67 × 10⁻⁷ 0·61 (0·44–0·83) 2·70 × 10⁻⁷
Death 10% (3216/670/40) 6% (228/29/1) A 0·59 (0·40–0·85) 0·003 0·60 (0·31–0·82) 0·004
INPP4B (rs77389579, chromosome 4, G→T)
Severe malaria 6% (3407/516/14) 4% (2019/188/2) A 0·61 (0·51–0·72) 4·48 × 10⁻⁹ 0·64 (0·53–0·77) 4·79 × 10⁻⁹
Cerebral malaria 6% (3407/516/14) 5% (1113/109/1) A 0·63 (0·51–0·78) 1·48 × 10⁻⁵ 0·66 (0·52–0·83) 1·64 × 10⁻⁵
Severe malarial anaemia 6% (3407/516/14) 4% (613/52/1) A 0·56 (0·42–0·75) 3·57 × 10⁻⁵ 0·60 (0·43–0·82) 5·35 × 10⁻⁵
Respiratory distress 6% (3407/516/14) 4% (625/58/0) A 0·58 (0·44–0·78) 8·53 × 10⁻⁵ 0·62 (0·46–0·83) 9·54 × 10⁻⁵
Death 6% (3407/516/14) 4% (241/19/0) A 0·50 (0·31–0·80) 0·001 0·48 (0·28–0·80) 0·001
ABO (rs8176719, chromosome 9; blood group O vs non-blood group O)‡
Severe malaria 26% (256/3632) 31% (198/2032) R 0·73 (0·65–0·81) 3·99 × 10⁻⁹ 0·74 (0·66–0·82) 6·26 × 10⁻⁸
Cerebral malaria 26% (256/3632) 30% (198/2032) R 0·77 (0·68–0·88) 9·36 × 10⁻⁵ 0·78 (0·69–0·92) 0·0004
Severe malarial anaemia 26% (256/3632) 32% (198/2032) R 0·66 (0·56–0·78) 8·45 × 10⁻⁷ 0·67 (0·78–0·79) 3·68 × 10⁻⁶
Respiratory distress 26% (256/3632) 31% (198/2032) R 0·70 (0·59–0·83) 2·74 × 10⁻⁵ 0·71 (0·60–0·84) 6·45 × 10⁻⁵
Death 26% (256/3632) 32% (198/2032) R 0·67 (0·52–0·87) 0·002 0·67 (0·52–0·87) 0·002
(Table 2 continues on next page)
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Hospital with features of severe falciparum malaria. 
Between Aug 1, 2006, and Sept 30, 2010, 3949 infants 
born in the local community were recruited as controls. 
The clinical, demographic, and laboratory characteristics 
of severe malaria cases and community controls are 
summarised in table 1. The flow of cases through the 
study is shown in the appendix (p 29).
Overall, 263 (12%) of 2244 children with severe malaria 
died in hospital. Mortality was highest in the subgroup 
with clinical features of cerebral malaria (196 of 
1233 [16%]) and lowest in those who manifested other 
features of severe malaria (21 of 436 [5%]). 644 (29%) cases 
had two or more common phenotypes of severe malaria 
(figure 1). 
The results of association analyses between severe 
malaria overall and all the polymorphisms under 
investigation are summarised in figure 2 and in the 
appendix (pp 7–16). Significant associations were found 
with severe malaria overall—or with at least one of its 
pheno types—for polymorphisms in 15 of 70 genes investi-
gated. The genes and locations were ABO, ATP2B4, ARL14, 
CD40LG, FREM3, INPP4B, G6PD, HBA (both HBA 1 and 
HBA2), HBB, IL10, LPHN2 (also known as ADGRL2), 
LOC727982, RPS6KL1, CAND1, and GNAS for autosomal-
related (table 2) and X-chromosome-related (table 3) 
polymorphisms. Data pertaining to the polymorphisms 
in CAND1 and GNAS are presented in the appendix 
(pp 7–16). Analyses done in terms of genotypic groups are 
summarised in the appendix (p 17). Associations seemed 
mostly to be additive and pronounced in homo zygotes. 
However, exceptions included G6PD and RPS6KL1, for 
which opposite effects were seen in hetero zygous and 
homozygous children, and IL10, for which protection was 
restricted to homozygotes. 
As anticipated, the strongest association with risk of 
severe malaria was with rs334 in HBB, which leads to the 
sickle-cell trait (adjusted OR 0·15, 95% CI 0·11–0·20; 
p=2·61 × 10–⁵⁸), with similar effect sizes for all three major 
severe malaria phenotypes (table 2; appendix pp 7–16). 
Strong associations with risk of severe malaria were also 
seen for polymorphisms in ABO and HBA, including 
rs8176719 in ABO (representing blood group O; adjusted 
Frequency (%) of derived 
allele in controls 
(normal/het/hom [n])
Frequency (%) of derived 
allele in cases 
(normal/het/hom [n])
Model* Unadjusted Adjusted†
OR (95% CI) p value OR (95% CI) p value
(Continued from previous page)
ABO (rs8176746, chromosome 9; C→A)§
Severe malaria 13% (2970/878/76) 17% (1529/622/76) A 1·37 (1·22–1·55) 9·60 × 10⁻⁹ 1·38 (1·22–1·50) 2·38 × 10⁻⁷
Cerebral malaria 13% (2970/878/76) 16% (870/317/36) A 1·23 (1·06–1·43) 0·005 1·22 (1·04–1·42) 0·01
Severe malarial anaemia 13% (2970/878/76) 18% (459/196/27) A 1·44 (1·20–1·73) 8·50 × 10⁻⁵ 1·44 (1·19–1·74) 0·0001
Respiratory distress 13% (2970/878/76) 18% (474/178/31) A 2·55 (1·66–3·92) 1·79 × 10⁻⁵ 2·42 (1·56–3·76) 8·04 × 10⁻⁵
Death 13% (2970/878/76) 17% (2181/169/8) A 1·28 (0·96–1·71) 0·08 1·29 (0·96–1·72) 0·08
HBB (rs334; chromosome 11; A→T)
Severe malaria 8% (3320/596/33) 1% (2159/57/11) H 0·14 (0·12–0·21) 6·81 × 10⁻⁵⁹ 0·15 (0·11–0·20) 2·61 × 10⁻⁵⁸
Cerebral malaria 8% (3320/596/33) 2% (1185/29/8) H 0·14 (0·09–0·21) 8·64 × 10⁻³⁹ 0·14 (0·09–0·20) 1·67 × 10⁻³⁸
Severe malarial anaemia 8% (3320/596/33) 2% (666/9/8) H 0·07 (0·04–0·15) 2·11 × 10⁻³¹ 0·07 (0·03–0·17) 2·61 × 10⁻³¹
Respiratory distress 8% (3320/596/33) 2% (664/13/7) H 0·11 (0·06–0·19) 8·41 × 10⁻²⁸ 0·11 (0·06–0·20) 1·62 × 10⁻²⁷
Death 8% (3320/596/33) 3% (242/11/3) H 0·26 (0·14–0·48) 1·96 × 10⁻⁷ 0·26 (0·14–0·49) 2·41 × 10⁻⁷
RPS6KL1 (rs3742785, chromosome 14; C→A)
Severe malaria 29% (1935/1422/357) 30% (1032/896/187) H 1·20 (1·08–1·34) 0·001 1·18 (1·05–1·33) 0·001
Cerebral malaria 29% (1935/1422/357) 29% (584/491/95) H 1·18 (1·03–1·35) 0·01 1·19 (1·03–1·37) 0·01
Severe malarial anaemia 29% (1935/1422/357) 32% (293/292/65) H 1·33 (1·12–1·57) 0·001 1·37 (1·15–1·64) 0·001
Respiratory distress 29% (1935/1422/357) 28% (341/260/55) H 1·06 (0·89–1·26) 0·45 1·06 (0·89–1·27) 0·5
Death 29% (1935/1422/357) 26% (140/95/18) H 0·98 (0·75–1·28) 0·91 0·99 (0·76–1·29) 0·96
HBA (–α³·⁷-thalassaemia, chromosome 16; insertion/deletion)
Severe malaria 40% (1356/1953/637) 36% (853/1026/264) A 0·82 (0·76–0·89) 6·59 × 10⁻⁷ 0·83 (0·76–0·90) 2·06 × 10⁻⁶
Cerebral malaria 40% (1356/1953/637) 37% (458/590/141) A 0·83 (0·75–0·91) 0·0001 0·83 (0·76–0·92) 0·0001
Severe malarial anaemia 40% (1356/1953/637) 34% (275/299/65) A 0·72 (0·64–0·82) 1·55 × 10⁻⁶ 0·72 (0·65–0·84) 5·45 × 10⁻⁶
Respiratory distress 40% (1356/1953/637) 35% (272/311/79) A 0·78 (0·69–0·89) 0·0001 0·79 (0·70–0·90) 0·0002
Death 40% (1356/1953/637) 33% (108/117/24) A 0·70 (0·57–0·85) 0·0003 0·72 (0·59–0·88) 0·0004
When more than one SNP was genotyped at a locus, we show ORs for the SNP with the lowest p value for severe malaria or any one of its phenotypes. Individuals with multiple phenotypes are included in each of those 
phenotype groups for analysis. het=heterozygous. hom=homozygous. OR=odds ratio. SNP=single nucleotide polymorphism. *Statistical models were additive (A), heterozygous (H), or recessive (R). †Adjusted for 
ethnic group, gender, and rs334. ‡The recessive model for rs8176719 is presented and represents blood group O. §The derived allele of rs8176746 identifies blood group B. 
Table 2: Polymorphisms with significant signals of association in different severe malaria phenotypes
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OR 0·74, 95% CI 0·66–0·72; p=6·26 × 10–⁸), rs8176746 
in ABO (identifying blood group B; 1·38, 95% CI 
1·22–1·50; p=2·38 × 10–⁷), and a 3·7 kb deletion in HBA 
(–α³·⁷-thalassaemia; 0·83, 0·76–0·90; p=2·06 × 10–⁶).
Further polymorphisms associated with severe malaria 
were noted for rs1541255 in ATP2B4 (adjusted OR 0·76, 
95% CI 0·63–0·92; p=0·001) and rs186873296 located in 
an intergenic region between FREM3 and GYPE 
(0·64, 0·53–0·79; p=3·18 × 10–¹⁴). rs186873296 between 
FREM3 and GYPE was associated with similar levels of 
protection against all three major phenotypes of severe 
malaria and protected against inpatient mortality (table 2). 
The effect of rs186873296 was additive for severe malaria 
overall (heterozygosity, adjusted OR 0·57, 95% CI 
0·49–0·68; p=3·22 × 10–¹¹; homozygosity, 0·26, 0·11–0·62; 
p=0·002; appendix p 17). The rs186873296 FREM3 
Frequency (%) of derived 
allele in controls 
(normal/het/hom [n])
Frequency (%) of derived 
allele in cases (normal/het/
hom [n])
Model* Unadjusted Adjusted†
OR (95% CI) p value OR (95% CI) p value
CD40LG (rs3092945; T→C)
Severe malaria (male and female) 21% (2760/646/521) 26% (1459/388/379) A 1·14 (1·06–1·22) 0·0002 1·15 (1·06–1·23) 0·0002
Cerebral malaria (male and female) 21% (2760/646/521) 25% (815/199/209) A 1·32 (1·10–1·59) 0·003 1·37 (1·13–1·67) 0·003
Severe malarial anaemia (male and 
female)
21% (2760/646/521) 26% (442/121/120) A 1·17 (1·05–1·31) 0·0001 1·18 (1·05–1·33) 0·003
Respiratory distress (male and female) 21% (2760/646/521) 25% (454/128/98) A 1·28 (1·01–1·63) 0·04 1·27 (1·09–1·64) 0·04
Death (male and female) 21% (2760/646/521) 25% (454/128/98) A 1·30 (0·88–1·92) 0·18 1·32 (0·88–2·00) 0·15
CD40LG (rs3092945; T→C)
Severe malaria (female) 21% (1215/646/81) 25% (614/388/80) A 1·25 (1·10–1·42) 0·0004 1·28 (1·13–1·45) 0·0002
Cerebral malaria (female) 21% (1215/646/81) 26% (355/199/48) A 1·89 (1·30–2·76) 0·001 1·23 (1·05–1·43) 0·007
Severe malarial anaemia (female) 21% (1215/646/81) 25% (181/121/26) A 1·33 (1·10–1·62) 0·003 1·36 (1·12–1·64) 0·001
Respiratory distress (female) 21% (1215/646/81) 24% (182/128/15) A 1·29 (1·01–1·63) 0·03 1·31 (1·03–1·66) 0·02
Death (female) 21% (1215/646/81) 24% (182/128/15) A 1·30 (0·88–1·92) 0·18 1·32 (0·90–1·95) 0·15
CD40LG (rs3092945; T→C)
Severe malaria (male) 78% (440/0/1545) 73% (299/0/845) HM 0·83 (0·70–0·99) 0·03 0·80 (0·68–0·95) 0·01
Cerebral malaria (male) 78% (440/0/1545) 76% (161/0/460) HM 0·84 (0·68–1·04) 0·11 0·81 (0·66–1·00) 0·05
Severe malarial anaemia (male) 78% (440/0/1545) 73% (94/0/261) HM 0·81 (0·63–1·05) 0·12 0·79 (0·61–1·02) 0·07
Respiratory distress (male) 78% (440/0/1545) 75% (83/0/272) HM 0·95 (0·72–1·23) 0·71 0·93 (0·71–1·21) 0·61
Death (male) 78% (440/0/1545) 75% (83/0/272) HM 0·93 (0·62–1·40) 0·75 0·91 (0·61–1·36) 0·65
G6PD (rs1050828; C→T)
Severe malaria (male and female) 19% (2863/639/438) 19% (1643/306/271) H 0·82 (0·70–0·97) 0·01 0·80 (0·68–0·96) 0·01
Cerebral malaria (male and female) 19% (2863/639/438) 18% (921/168/131) H 0·80 (0·65–0·98) 0·02 0·79 (0·64–0·97) 0·02
Severe malarial anaemia (male and 
female)
19% (2863/639/438) 23% (479/90/111) R 1·60 (1·26–2·03) 0·0001 1·72 (1·33–2·22) 0·0001
Respiratory distress (male and female) 19% (2863/639/438) 18% (510/98/72) H 0·90 (0·74–1·09) 0·28 0·91 (0·74–1·11) 0·28
Death (male and female) 19% (2863/639/438) 18% (510/98/72) H 0·64 (0·46–0·89) 0·006 0·64 (0·45–0·90) 0·006
G6PD (rs1050828; C→T)
Severe malaria (female) 19% (1250/639/62) 18% (729/306/39) H 0·82 (0·70–0·97) 0·01 0·81 (0·69–0·96) 0·01
Cerebral malaria (female) 19% (1250/639/62) 18% (410/168/122) H 0·80 (0·65–0·98) 0·03 0·79 (0·65–0·97) 0·02
Severe malarial anaemia (female) 19% (1250/639/62) 17% (224/90/11) H 0·79 (0·61–1·03) 0·07 0·78 (0·60–1·02) 0·06
Respiratory distress (female) 19% (1250/639/62) 19% (215/198/12) H 0·89 (0·58–1·38) 0·61 0·88 (0·68–1·14) 0·35
Death (female) 19% (1250/639/62) 19% (215/198/12) H 0·56 (0·37–0·85) 0·004 0·57 (0·38–0·86) 0·005
G6PD (rs1050828; C→T)
Severe malaria (male) 18% (1613/0/376) 20% (914/0/232) HM 1·11 (0·92–1·33) 0·26 1·08 (0·90–1·30) 0·36
Cerebral malaria (male) 18% (1613/0/376) 18% (511/0/109) HM 0·92 (0·72–1·17) 0·48 0·91 (0·72–1·15) 0·45
Severe malarial anaemia (male) 18% (1613/0/376) 28% (255/0/100) HM 1·72 (1·32–2·23) 6·98 × 10⁻⁵ 1·68 (1·30–2·17) 0·0001
Respiratory distress (male) 18% (1613/0/376) 17% (295/0/60) HM 0·89 (0·66–1·21) 0·89 0·87 (0·64–1·17) 0·36
Death (male) 18% (1613/0/376) 17% (295/0/60) HM 0·77 (0·48–1·24) 0·28 0·77 (0·48–1·23) 0·26
Data are from models that were most significant. Individuals with multiple phenotypes are included in each of those phenotype groups for analysis. Analyses were run on males and females separately and 
combined, using standard meta-analysis techniques. het=heterozygous. hom=homozygous. OR=odds ratio. SNP=single nucleotide polymorphism. *Statistical models were additive (A), heterozygous (H), 
hemizygous male (HM), or recessive (R). †Adjusted for ethnic group, gender, and rs334 genotype.
Table 3: X-chromosome SNPs with significant signals of association in different severe malaria phenotypes
Articles
www.thelancet.com/haematology   Vol 5   August 2018 341
polymorphism also correlated closely with the poly mor-
phism that is specific to the Dantu blood group antigen 
(concordance 1907 of 1938 [98%]; appendix p 28).
Because some individuals with more than one phenotype 
for severe malaria were included in more than one 
analysis group, analyses were also done in which 
individuals were only included in single analytical groups 
(appendix pp 18–23, 30). On visual inspection and 
comparison, these analyses were largely concordant with 
our overall analyses. To exclude the possibility of epistasis 
between individual malaria-associated genes, which holds 
the potential for concealing true associations in overall 
analyses, pairwise analyses were done to test for gene–
gene interactions between the most significant poly-
morphisms (appendix pp 24, 31). The smallest p value 
we found (p=0·02) was between polymorphisms in 
HBB (rs334) and HBA loci, which result in sickle-cell 
trait or sickle-cell disease and in –α³·⁷-thalassaemia, 
respectively. This analysis showed evidence of a negative 
interaction between sickle-cell trait and –α³·⁷-thalassaemia 
through which the protective effects of each polymorphism 
inherited independently seemed to be lost when both were 
inherited together (appendix pp 24, 32).
The effect of polymorphisms associated with risk for 
severe malaria on other variables of severe malaria—
including parasite densities (the number of parasites in 
circulation, assessed by visually counting parasites on 
peripheral blood films) or haematological indices—was 
also investigated. Three significant associations were 
noted between candidate polymorphisms and malaria 
parasite densities (table 4). Parasitaemia was significantly 
lower among cases with severe malaria and sickle-cell 
trait compared with those with severe malaria and 
normal haemoglobin (p=3·66 × 10–⁶), among homo-
zygotes for the derived allele (GG) at rs1541255 of ATP2B4 
compared with homozygotes for the ancestral allele (AA; 
p=0·04), and among children with blood group O 
compared with non-blood group O cases (p=0·02). 
Significant associations were also noted between 
polymorphisms and haematological indices (appendix 
p 25). Haemoglobin concentrations and red-blood-cell 
counts were significantly higher in children with sickle-
cell trait and significantly lower in those with sickle-cell 
disease compared with children with normal haemo-
globin, whereas haemoglobin concen trations were 
higher in children with the rs186873296 SNP in FREM3 
homozygous for the derived allele (GG) compared with 
those homozygous for the ancestral allele (AA; 
appendix p 25).
The proportion of variance in the risk of severe malaria 
that could be accounted for by genetic polymorphisms 
and other factors was estimated, and 5·2% of the total 
variance in the overall risk of severe malaria was accounted 
for by polymorphisms in 12 genes: HBB, FREM3, ABO, 
HBA (HBA1 and HBA2), ATP2B4, LOC727982, ARL14, 
IL10, RPS6KL1, LPHN2 (ADGRL2), INPP4B, and EMR1 
(appendix p 34). Inheritance of sickle-cell trait at HBB 
(rs334) accounted alone for 2·9% of the total variance, 
FREM3 (rs186873296) for 0·6%, and the remaining ten 
genes had a combined total of 1·7% (appendix pp 26, 27). 
Ethnic origin contributed to 1·9% of the total variance in 
Patients (n) Parasite density per µL p value*
ATP2B4 (rs1541255)
Normal (AA) 989 43 540 (37 370–50 729) ..
Heterozygous (AG) 1005 40 027 (34 396–46 579) 0·72
Homozygous (GG) 181 28 635 (20 033–40 929) 0·04
IL10 (rs1800890)
Normal (AA) 1294 39 224 (34 329–44 817) ..
Heterozygous (AT) 808 42 156 (35 612–49 902) 0·78
Homozygous (TT) 95 46 900 (28 675–76 707) 0·77
LPHN2 (also known as ADGRL2; rs72933304)
Normal (CC) 1880 40 179 (35 962–44 890) ..
Heterozygous (AC) 292 42 316 (31 939–56 066) 0·93
Homozygous (AA) 8 36 451 (6660–199 493) 0·99
LOC727982 (rs1371478)
Normal (CC) 1065 40 204 (34 692–46 591) ..
Heterozygous (CT) 946 41 676 (35 640–48 734) 0·94
Homozygous (TT) 162 34 272 (23 482–50 019) 0·72
ARL14 (rs75731597)
Normal (AA) 1726 41 555 (37 009–46 660) ..
Heterozygous (AC) 394 34 628 (27 171–44 130) 0·37
Homozygous (CC) 18 34 337 (11 042–106 776) 0·94
FREM3 (rs186873296)
Normal (AA) 1933 41 607 (37 305–46 405) ..
Heterozygous (AG) 232 32 556 (23 759–44 611) 0·31
Homozygous (GG) 5 119 644 (13 995–1 022 828) 0·59
INPP4B (rs77389579)
Normal (GG) 1985 39 666 (35 611–44 182) ..
Heterozygous (GT) 186 48 607 (34 175–69 133) 0·52
Homozygous (TT) 2 293 153 (9811–8 759 196) 0·48
ABO (rs8176719)†
Non-blood group O 1161 46 170 (40 068–54 455) ..
Blood group O 1026 35 092 (30 220–40 749) 0·02
ABO (rs8176746)‡
Normal (CC) 1504 38 608 (34 118–43 688) ..
Heterozygous (AC) 613 44 829 (36 937–54 406) 0·40
Homozygous (AA) 74 46 817 (26 814–81 739) 0·78
HBB (rs334)
Normal (AA) 2125 42 857 (38 648–47 525) ..
Heterozygous (AT) 56 8649 (4575–16 350) 3·66 × 10⁻⁶
Homozygous (TT) 11 8850 (2103–37 235) 0·08
RPS6KL1 (rs3742785)
Normal (CC) 1015 42 920 (36 915–44 901) ..
Heterozygous (AC) 881 39 668 (33 743–46 633) 0·76
Homozygous (AA) 185 44 458 (31 235–63 279) 0·98
HBA (α⁻³·⁷-thalassaemia)
Normal 843 39 969 (33 877–47 157) ..
Heterozygous 1009 40 292 (34 639–46 867) 0·99
Homozygous 257 38 243 (28 345–51 598) 0·96
(Table 4 continues on next page)
Articles
342 www.thelancet.com/haematology   Vol 5   August 2018
the risk of contracting severe malaria and accounted for 
less than 10% of the variance from any of the individual 
genes. Gender contributed only 0·009% of the total 
variance in the risk of severe malaria. Thus, 93% of the 
variance in the overall risk observed could not be 
accounted for in our model. The inheritance of 
polymorphisms in FREM3 and INPP4B were in high 
linkage disequilibrium (appendix p 33); each constituted a 
proportion of the variance attributable to the other, 
accounting for the lower variances for these 
polymorphisms individually when combined in one 
model (appendix pp 26, 27).
Discussion
We found significant associations between risk for severe 
malaria and polymorphisms in 15 genes. Although data 
for some of these genes have been reported previously,11 
our analysis includes new candidates that have been 
identified from subsequent genome-wide association 
studies9,12 and provides additional data about the relations 
between specific polymorphisms and a range of clinical 
and laboratory phenotypes among severe malaria cases 
(eg, malaria parasite densities and haematological 
indices). Of note, most of the significant associations 
were linked to genes that have a role in red-blood-cell 
phenotype or function, the haematological outcomes for 
some of which remain largely undocumented.
In keeping with the epidemiological setting of our 
study site, within an area of relatively low P falciparum 
transmission, cerebral malaria accounted for the largest 
proportion of severe malaria cases and was associated 
with the highest mortality.18 However, we also recorded 
considerable overlap in the phenotypic presentation of 
severe malaria. This observation, which accords with 
those of previous studies,19 made it difficult for us to 
detect syndrome-specific effects, and is a weakness of 
our case-control approach. Moreover, we confirmed the 
strong protective advantage against severe malaria of 
several well established candidate polymorphisms, 
including inherited red-blood-cell characteristics 
resulting in sickle-cell trait, G6PD deficiency, and blood 
group O. The relations between these polymorph-
isms and various forms of clinical malaria have been 
discussed previously.20 Although we also confirmed 
the long-recognised protective genetic advantage of 
–α³·⁷-thalass aemia against severe malaria, by contrast 
with previous reports,21 we noted that protection was not 
restricted to severe malaria anaemia but was seen equally 
against all other phenotypes of severe malaria. This 
finding is most likely accounted for by the limited 
statistical power of earlier reports,21 emphasising the 
need for caution when interpreting the results of smaller 
studies.
Our study confirms the relevance of associations 
between severe malaria and several genes that have been 
described previously. ATP2B4 on chromosome 1 encodes 
for PMCA4, the main red-blood-cell calcium (Ca²+) 
pump.22 On the basis of studies conducted in vitro, 
variant forms of ATP2B4 have been shown to affect 
platelet and endothelial function.23 Other genes of 
interest relate to the glycophorin molecules, which have 
long been recognised as receptors for red-blood-cell 
invasion by P falciparum merozoites.24 In the case of 
GYPA, red-blood-cell invasion is mediated through its 
specific interaction with Duffy binding like (DBL) 
domains on the P falciparum merozoite surface protein 
EBA-175,25 but some strains of P falciparum parasites can 
also invade through pathways that involve interactions 
between other glycophorin molecules and a range of 
alternative merozoite ligands.26 Mutant forms of these 
glycophorin molecules could, therefore, be attractive 
targets for drug and vaccine development.
A significant association signal of ATP2B4 was 
first identified in a genome-wide association case-control 
study of severe malaria undertaken in Ghana, and 
replicated in subsequent severe malaria case-control 
studies.20 However, to the best of our knowledge, the 
haematological and wider health outcomes of this 
polymorphism, and its association with risk for specific 
phenotypes of severe malaria, were not known previously. 
The polymorphism rs1541255 in ATP2B4 was common 
in our study population, with an allele frequency of 
33% among controls, consistent with selection through a 
survival advantage against malaria. Association signals 
detected within ATP2B4 in case-control studies of severe 
malaria undertaken to date might reflect their linkage 
disequilibrium with a functional mutation in the 
promoter region of ATP2B4 that results in reduced 
expression of red-blood-cell PMCA4 and, as a result, in 
reduced red-blood-cell Ca²+ extrusion.27 In view of the 
central role that Ca²+ has in the physiology of P falciparum 
red-blood-cell invasion,28 it is noteworthy that homo- 
zygosity at rs1541255 was one of the few genotypes to be 
associated with reduced parasite densities in our study. 
Ca²+ is also important in both clumping of P falciparum-
infected red blood cells and in their sequestration to the 
Patients (n) Parasite density per µL p value*
(Continued from previous page)
CD40LG (rs3092945)
Normal (TT) 1432 39 307 (34 627–44 619) ..
Heterozygous (CT) 383 44 242 (34 624–56 532) 0·67
Homozygous (CC) 375 42 007 (32 789–53 815) 0·88
G6PD (rs1050828)
Normal (CC) 1616 41 464 (36 808–46 708) ..
Heterozygous (CT) 301 41 157 (31 232–54 236) 0·99
Homozygous (TT) 267 35 063 (26 158–47 000) 0·55
Data are geometric mean (95% CI). *Adjusted for ethnicity, gender and rs334 genotype; for this subanalysis of parasite 
densities, we judged p<0·05 significant. †The rs8176719 polymorphism identifies blood group O in the homozygous 
deletion form. ‡The derived allele of rs8176746 identifies blood group B. 
Table 4: Plasmodium falciparum parasite densities in patients with severe malaria and loci included in the 
univariate analysis 
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vascular endothelium, both of which could lead to severe 
and complicated malaria through the occlusion of blood 
vessels in essential tissues, including the brain.29 As such, 
several plausible explanations could account for how 
mutations in ATP2B4 might be relevant to protection 
against severe malaria that could potentially be exploited 
for development of therapeutic agents. Further studies 
are being done to confirm the precise mutation within 
ATP2B4 that is associated with malaria protection 
and describing its effects both on tissue-specific 
PMCA4 structure and function and on malaria-specific 
pathophysiological processes.
A second association, previously identified in a genome-
wide association study of severe malaria that included a 
subset of data and samples in our study,9,12 was seen at SNP 
rs186873296 in FREM3. The rs186873296 association tags a 
haplotype for the neighbouring region comprising GYPA, 
GYPB, and GYPE9 and, in particular, a hybrid gene 
comprising GYPA and GYPB, which encodes a blood 
antigen known as Dantu.12 Instead of expressing normal 
GYPA and GYPB molecules, people with Dantu produce a 
hybrid molecule that consists of the extracellular domain of 
GYPB and the transmembrane plus intra cellular domains 
of GYPA.30 In our extended sample set of severe malaria 
cases from Kenya, we found that the rs186873296 FREM3 
polymorphism correlated closely with the polymorphism 
that is specific to Dantu.12 A second associ ation signal, at 
INPP4B within the same gene region, seemed to also 
account for its close chromosomal proximity and strong 
linkage disequilibrium with Dantu. This finding supports 
the conclusion that the statistical association between 
severe malaria risk and SNPs in both FREM3—a gene of 
unknown biological relevance—and INPP4B are not in 
themselves causal with respect to malaria susceptibility but 
rather their associations might be accounted for by their 
close linkage disequilibrium with Dantu, which could most 
plausibly provide a malaria-protective mechanism on the 
basis of biological theory. Never theless, by contrast with 
sickle-cell trait, ATP2B4, and blood group O, we saw no 
discernible effect of rs186873296 on parasite densities in 
severe malaria cases within our study.
On the one hand, although the Dantu polymorphism 
does not seem to offer protection by reducing red-blood-
cell parasite invasion, the absence of any apparent effect 
on parasite densities might simply show that patients 
have severe malaria, and does not exclude the possibility 
that the malaria-protective effect of Dantu might be 
restricted to red-blood-cell invasion via a glycophorin-
specific pathway by a subset of P falciparum parasites. On 
the other hand, the mechanism by which Dantu protects 
against severe malaria might not be mediated by reduced 
parasite invasion at all, but instead relate to the 
pathophysiology of malaria more broadly. Further work 
will be needed to elucidate the mechanisms definitively.
Comparative genetic analysis of chimpanzees and 
human beings has shown that the GYPA, GYPB, and 
GYPE loci lie in an area of the genome that has 
characteristics of ancient balancing selection.12 Thus, 
Dantu might also be under balancing selection, in which 
its positive selection by malarial disease might be 
balanced by negative selection from a biological 
disadvantage yet to be discovered. As such, it will also be 
important to ascertain whether homozygosity for Dantu 
is associated with any negative outcomes.
The associations between sickle-cell trait and 
homozygosity for rs186873296 in FREM3 and haemato-
logical indices among severe malaria cases are 
noteworthy. The most likely reason for the high 
haemoglobin concentrations in cases with both these 
genotypes is that such children are protected from all 
forms of clinical malaria that result cumulatively in 
higher levels of anaemia in children without these 
protective polymorphisms. Although this protection is 
well recognised for sickle-cell trait,21 further studies will 
be needed to show that this is also true for FREM3. 
Moreover, the lower mean red-blood-cell volume and 
higher red-blood-cell count that we observed in sickle-cell 
trait cases is consistent with the findings from a previous 
study conducted in the same population.31
How the remaining polymorphisms described both 
here and in previous studies can be exploited for 
therapeutic advantage, in terms of their associations 
with the overall risk of severe malaria, remains unclear. 
For example, in agreement with previous studies,32,33 
we found that polymorphisms in CD40LG were 
associated with a significantly increased risk of severe 
malaria, but by contrast with findings of a case-control 
study of severe childhood malaria in Tanzania,20 we 
found no evidence that this association was specific to a 
phenotype of severe malaria. The absence of an 
association between CD40LG and a specific phenotype 
of severe malaria in our current study presumably 
reflects the greater power of our study relative to earlier 
studies, because small studies are prone to false-positive 
findings as a result of statistical chance. Likewise, 
although significant associations were seen between 
severe malaria and polymorphisms in seven additional 
genes (IL10, LPHN2 [ADGRL2], LOC727982, ARL14, 
RPS6KL1, CAND1, and GNAS), without further data 
their potential for translation remains elusive.
Despite strong associations between severe malaria and 
several candidate polymorphisms, our analyses suggest 
that together they only accounted for a small 
proportion (5·2%) of the total variance in risk for 
contracting severe malaria in Kilifi County overall, only a 
quarter of the overall heritability attributed in an earlier 
study.3 Perhaps additional genetic associations remain to 
be discovered, our modelling approach was inadequate, or 
the proportion of variance that we attributed to heritability 
in our previous study was overestimated by the verbally 
reported pedigree-based method that we used,3 because of 
confounding between families and household-related 
environmental factors that were not captured completely 
by fitting both these terms in our model. The low variance 
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attributable to genes with strong individual protective 
effects might be caused partly by the low population 
frequencies of some of these alleles. For example, the 
rs334 mutation in HBB contributes only 2·9% to the total 
variance in risk for severe malaria despite its large effect 
size because protection is only afforded to a small 
proportion (about 15%) of the population. 
In a previous study,32 a higher proportion of variance 
was accounted for by both HBB (6·3%) and other 
polymorphisms compared with the proportions we 
reported in our study. However, the estimates in that 
previous study were not adjusted for the ascertainment 
bias that will have resulted from the study’s case-control 
design. It is also not clear whether the earlier estimates 
were generated on the observed or underlying liability 
scale, resulting in bias from the overall prevalence. These 
failures to account for prevalence and study design in 
previous studies highlight the need to apply the 
adjustments we made to compare heritability estimates 
across populations validly.
In conclusion, in accordance with findings of previous 
studies, we report that the strongest protective genetic 
associations against severe malaria all relate consistently 
to polymorphisms that affect the structure or function of 
red blood cells. As a result, some polymorphisms have 
been selected to very high levels. For example, almost 
two-thirds of the population in our study area were 
affected by –α³·⁷-thalassaemia, and large proportions of 
the population are affected by other polymorphisms, 
many of which have unknown haematological impli-
cations. Moreover, because such polymorphisms are so 
common, many children inherit more than one, with 
outcomes that—in most cases—are even less well 
understood. It will be important to better understand the 
mechanisms by which these red-blood-cell conditions 
protect against severe malaria, along with their broader 
haematological outcomes. Future research should 
determine how malaria-protective mechanisms might be 
emulated to uncover potential new approaches to the 
prevention and treatment of severe malaria.
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